Magnasense logotype


Brand Change Announcement: AegirBio AB has officially changed its name to Magnasense AB. The new website,, launched on 9 July 2024, with redirects from

AegirBio’s CEO Marco Witteveen to Attend SalivaDirect's 3rd Annual Conference in Washington, DC, June 5-7, 2024

Lund May 29, 2024. AegirBio’s CEO Marco Witteveen willparticipate in SalivaDirect's 3rd Annual Conference on June 5-7 at The Darcy Hotel in Washington, DC

This prestigious 3-day event is tailored to foster dynamic discussions and collaborations, offering an ideal platform to exchange innovative ideas with some of the most brilliant minds in the industry. As attendee, AegirBio is eagerly anticipating the opportunity to gain insights from esteemed members of the company’s network and renowned leaders in the diagnostic world.

"We are excited to participate in SalivaDirect's 3rd Annual Conference," remarked Marco Witteveen. "This event presents an invaluable opportunity to engage in inspiring discussions with fellow laboratories, diagnostic developers, academics, and public health practitioners. Together, we aim to drive the industry forward and accelerate progress in infectious disease testing."

AegirBio looks forward to contributing to the vibrant dialogue and forging meaningful collaborations that will shape the future of diagnostic innovation and global health.

About Aegirbio

AegirBio is a Swedish diagnostics company founded in 2019 to offer tests to monitor and optimize the dosage of biological drugs via its unique patented technology platform. In June 2020, AegirBio was listed on the Nasdaq First North Growth Market. The company's ambition is, in addition to bringing innovative diagnostic technology to the market, to make diagnostics more accessible, easier to use and to provide accurate and easily transferable results. For more information, see Aegirbio's website

The company's Certified Adviser is Eminova Fondkomission AB;

Related link: